Executive Director Zach Stanley describes the program and how to get involved, and recent college graduate Denise Mitchell gives us...

He describes what the funds will enable Artiva to do in the clinic, and why he believes the company's non-modified NK cell approach is...

Marcio Souza describes Praxis' small molecule and antisense oligonucleotide platforms, and previews key trials that will have near term data

Jacob Thaysen covers Illumina’s business today, including the NovaSeq X platform, multiomics, clinical and pharma industry applications,...

She describes how this PMO based antibody oligonucleotide conjugate works and why she believes the result validates her belief that...

She describes why she decided to move to the investment side and Sofinnova, what areas of science interest her today, and some thoughts...

Jay Backstrom describes the company's approach of targeting the latent form of growth factors, the importance of the upcoming SAPPHIRE...

He gives updates on programs such as IRAK4, STAT6, TYK2, and STAT3, and describes learnings in protein degradation that Kymera has...

Jay Olson shares learnings from a physician survey Oppenheimer conducted on obesity, and comments on Viking, Amgen, Madrigal, Acadia,...

David Lee describes the glioma brain cancer population this IHD1/2 targeting therapy is for, Servier's experience commercializing cancer...

Eliot Forster describes the scientific rational of inhibiting NT-3 while avoiding nerve growth factor and the side effects that come with...

He describes the unique science that Stoke was founded on, how phase 1/2a data in Dravet appears to show they are reversing this genetic...

Adrian Rawcliffe describes how the treatment works, the expected rollout and cost, and what this means for TCR therapies going forward.

Andrew Tsai shares his take on biotech and discusses Verona, Rapport, Atai Life Sciences, Intra-Cellular, Alto Neuro, Athira, and Relmada.

Co-founder and CEO Tim Guilliams describes the investors who led the round and how it will allow Healx to advance its lead program for...

CEO Greg Hamilton describes how patients who were diagnosed with this software platform had better outcomes, how it might increase the...

CEO Kevin Finney describes the rationale for using a TRβ agonist and how this program leverages Autobahn's brain-targeting chemistry...

He talks about the two different categories of companies based on their use of AI, and discusses what he looks for when evaluating them.

Yusuf Erkul explains the four components that go into getting mRNA to the right location in the body and to be translated in the right...

He describes clinical programs targeting COVID and TSLP, as well as emerging programs in the ADC space, TL1A, IL13, and more.